The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?
Abstract
:1. Introduction
2. Association from Population Studies
2.1. Baseline Cholesterol Level and the Risk of ICH
2.2. Repeated LDL-C Measurements and the Risk of ICH
3. Statins and Ezetimibe Clinical Trials and Intra-Cerebral Hemorrhage
4. Recent Data from PCSK9 Inhibitor Trials
5. Pathophysiology and Trying to Establish a Causal Association
6. Conclusions and Take-Home Message
Author Contributions
Funding
Conflicts of Interest
References
- Feigin, V.L.; Nguyen, G.; Cercy, K.; Johnson, C.O.; Alam, T.; Parmar, P.G.; Abajobir, A.A.; Abate, K.H.; Abd-Allah, F.; Abejie, A.N.; et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N. Engl. J. Med. 2018, 379, 2429–2437. [Google Scholar] [CrossRef]
- Feigin, V.L.; Roth, G.A.; Naghavi, M.; Parmar, P.; Krishnamurthi, R.; Chugh, S.; Mensah, G.A.; Norrving, B.; Shiue, I.; Ng, M.; et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016, 15, 913–924. [Google Scholar] [CrossRef] [Green Version]
- Krishnamurthi, R.V.; Moran, A.E.; Forouzanfar, M.H.; Bennett, D.A.; Mensah, G.A.; Lawes, C.M.; Barker-Collo, S.; Connor, M.; Roth, G.A.; Sacco, R.; et al. The global burden of hemorrhagic stroke: A summary of findings from the GBD 2010 study. Glob. Heart 2014, 9, 101–106. [Google Scholar] [CrossRef]
- Bruckdorfer, K.R.; Demel, R.A.; de Gier, J.; van Deenen, L.L.M. The effect of partial replacements of membrane cholesterol by other steroids on the osmotic fragility and glycerol permeability of erythrocytes. Biochim. Biophys. Acta (BBA) Biomembr. 1969, 183, 334–345. [Google Scholar] [CrossRef] [Green Version]
- Konishi, M.; Iso, H.; Komachi, Y.; Iida, M.; Shimamoto, T.; Jacobs, D.R., Jr.; Terao, A.; Baba, S.; Sankai, T.; Ito, M. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 1993, 24, 954–964. [Google Scholar] [CrossRef] [Green Version]
- Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 2017, 38, 2459–2472. [Google Scholar] [CrossRef] [Green Version]
- Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.; Keech, A.; Simes, J.; et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376, 1670–1681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sturgeon, J.D.; Folsom, A.R.; Longstreth, W.T., Jr.; Shahar, E.; Rosamond, W.D.; Cushman, M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007, 38, 2718–2725. [Google Scholar] [CrossRef]
- Noda, H.; Iso, H.; Irie, F.; Izumi, Y.; Doi, M.; Sairenchi, T.; Ohtaka, E.; Ohta, H. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: The Ibaraki prefectural health study. Circulation 2009, 120, 2136–2145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Dong, Y.; Qi, X.; Huang, C.; Hou, L. Cholesterol levels and risk of hemorrhagic stroke: A systematic review and meta-analysis. Stroke 2013, 44, 1833–1839. [Google Scholar] [CrossRef] [Green Version]
- Pétrault, M.; Casolla, B.; Ouk, T.; Cordonnier, C.; Bérézowski, V. Cerebral microbleeds: Beyond the macroscope. Int. J. Stroke 2019, 14, 468–475. [Google Scholar] [CrossRef]
- Lee, S.-H.; Bae, H.-J.; Yoon, B.-W.; Kim, H.; Kim, D.-E.; Roh, J.-K. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: Analysis of risk factors for multifocal signal loss lesions. Stroke 2002, 33, 2845–2849. [Google Scholar] [CrossRef]
- Wieberdink, R.G.; Poels, M.M.; Vernooij, M.W.; Koudstaal, P.J.; Hofman, A.; van der Lugt, A.; Breteler, M.M.; Ikram, M.A. Serum lipid levels and the risk of intracerebral hemorrhage: The Rotterdam Study. Arter. Thromb. Vasc. Biol. 2011, 31, 2982–2989. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Psaty, B.M.; Anderson, M.; Kronmal, R.A.; Tracy, R.P.; Orchard, T.; Fried, L.P.; Lumley, T.; Robbins, J.; Burke, G.; Newman, A.B.; et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J. Am. Geriatr. Soc. 2004, 52, 1639–1647. [Google Scholar] [CrossRef] [PubMed]
- Holme, I.; Aastveit, A.H.; Hammar, N.; Jungner, I.; Walldius, G. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med. 2009, 265, 275–287. [Google Scholar] [CrossRef] [PubMed]
- Stoekenbroek, R.M.; Boekholdt, S.M.; Luben, R.; Hovingh, G.K.; Zwinderman, A.H.; Wareham, N.J.; Khaw, K.-T.; Peters, R.J. Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: The EPIC-Norfolk prospective population study. Eur. Heart J. 2016, 37, 880–889. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amarenco, P.; Kim, J.S.; Labreuche, J.; Charles, H.; Abtan, J.; Béjot, Y.; Cabrejo, L.; Cha, J.K.; Ducrocq, G.; Giroud, M.; et al. A comparison of two LDL cholesterol targets after ischemic stroke. N. Engl. J. Med. 2020, 382, 9. [Google Scholar] [CrossRef]
- Ma, C.; Gurol, M.E.; Huang, Z.; Lichtenstein, A.; Wang, X.; Wang, Y.; Neumann, S.; Wu, S.; Gao, X. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: A prospective study, systematic review, and meta-analysis (P18-029-19). Neurology 2019, 3, e445–e457. [Google Scholar] [CrossRef]
- Rouleau, J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: Results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am. J. Med. 2005, 118, 28–35. [Google Scholar] [CrossRef]
- Schoenhagen, P.; Tuzcu, E.M.; Apperson-Hansen, C.; Wang, C.; Wolski, K.; Lin, S.; Sipahi, I.; Nicholls, S.J.; Magyar, W.A.; Loyd, A.; et al. Determinants of arterial wall remodeling during lipid-lowering therapy: Serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 2006, 113, 2826–2834. [Google Scholar] [CrossRef] [Green Version]
- Nissen, S.E.; Nicholls, S.J.; Sipahi, I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006, 295, 1556–1565. [Google Scholar] [CrossRef] [PubMed]
- Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009, 373, 1175–1182. [Google Scholar] [CrossRef]
- Waters, D.D.; Schwartz, G.G.; Olsson, A.G.; Zeiher, A.; Oliver, M.F.; Ganz, P.; Ezekowitz, M.; Chaitman, B.R.; Leslie, S.J.; Stern, T. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circultion 2002, 106, 1690–1695. [Google Scholar] [CrossRef]
- McKinney, J.S.; Kostis, W.J. Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials. Stroke 2012, 43, 2149–2156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pandit, A.K.; Kumar, P.; Kumar, A.; Chakravarty, K.; Misra, S.; Prasad, K. High-dose statin therapy and risk of intracerebral hemorrhage: A meta-analysis. Acta Neurol. Scand. 2016, 134, 22–28. [Google Scholar] [CrossRef] [PubMed]
- Laufs, U.; Gertz, K.; Huang, P.; Nickenig, G.; Böhm, M.; Dirnagl, U.; Endres, M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000, 31, 2442–2449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, X.S.; Zhang, Z.G.; Zhang, L.; Morris, D.C.; Kapke, A.; Lu, M.; Chopp, M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J. Cereb. Blood Flow Metab. 2006, 26, 787–796. [Google Scholar] [CrossRef] [Green Version]
- Collins, R.; Armitage, J.; Parish, S.; Sleight, P.; Peto, R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363, 757–767. [Google Scholar] [CrossRef] [PubMed]
- Goldstein, L.B.; Amarenco, P.; Szarek, M.; Callahan, A.; Hennerici, M.; Sillesen, H.; Zivin, J.A.; Welch, K.M.A. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008, 70, 2364–2370. [Google Scholar] [CrossRef]
- Fulcher, J.; O’Connell, R.; Voysey, M.; Emberson, J.; Blackwell, L.; Mihaylova, B.; Simes, J.; Collins, R.; Kirby, A.; Colhoun, H.; et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015, 385, 1397–1405. [Google Scholar]
- Sabatine, M.S.; Wiviott, S.D.; Im, K.; Murphy, S.A.; Giugliano, R.P. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: A meta-analysis. JAMA Cardiol. 2018, 3, 823–828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, Y.; Qiao, L.; Jiang, Z.; Dong, X.; Feng, H.; Gui, Q.; Lu, Y.; Liang, Y. Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: A systematic review and meta-analysis of 33 randomized controlled trials. Am. J. Transl. Res. 2020, 12, 463–477. [Google Scholar] [PubMed]
- Westover, M.B.; Bianchi, M.T.; Eckman, M.H.; Greenberg, S.M. Statin use following intracerebral hemorrhage: A decision analysis. Arch. Neurol. 2011, 68, 573–579. [Google Scholar] [CrossRef]
- Judge, C.; Ruttledge, S.; Costello, M.; Murphy, R.; Loughlin, E.; Alvarez-Iglesias, A.; Ferguson, J.; Gorey, S.; Nolan, A.; Canavan, M.; et al. Lipid lowering therapy, low-density lipoprotein level and risk of intracerebral hemorrhage–A meta-analysis. J. Stroke Cerebrovasc. Dis. 2019, 28, 1703–1709. [Google Scholar] [CrossRef]
- Saliba, W.; Rennert, H.S.; Barnett-Griness, O.; Gronich, N.; Molad, J.; Rennert, G.; Auriel, E. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology 2018, 91, e400–e409. [Google Scholar] [CrossRef]
- Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; McCagg, A.; White, J.A.; Théroux, P.; Darius, H.; Lewis, B.S.; Ophuis, T.O.; Jukema, J.W.; et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372, 2387–2397. [Google Scholar] [CrossRef] [Green Version]
- Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 2017, 376, 1713–1722. [Google Scholar] [CrossRef] [PubMed]
- Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 2018, 379, 2097–2107. [Google Scholar] [CrossRef] [PubMed]
- Giugliano, R.P.; Pedersen, T.R.; Park, J.-G.; De Ferrari, G.M.; Gaciong, Z.A.; Ceska, R.; Toth, K.; Gouni-Berthold, I.; Lopez-Miranda, J.; Schiele, F.; et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet 2017, 390, 1962–1971. [Google Scholar] [CrossRef]
- Milionis, H.; Barkas, F.; Ntaios, G.; Papavasileiou, V.; Vemmos, K.; Michel, P.; Elisaf, M. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk. Eur. J. Intern. Med. 2016, 34, 54–57. [Google Scholar] [CrossRef] [Green Version]
- Ooneda, G.; Yoshida, Y.; Suzuki, K.; Shinkai, H.; Hori, S.; Kobori, K.; Takayama, Y.; Sekiguchi, M. Smooth muscle cells in the development of plasmatic arterionecrosis, arteriosclerosis, and arterial contraction. J. Vasc. Res. 1978, 15, 148–156. [Google Scholar] [CrossRef] [PubMed]
- Bang, O.Y.; Saver, J.L.; Liebeskind, D.S.; Starkman, S.; Villablanca, P.; Salamon, N.; Buck, B.; Ali, L.; Restrepo, L.; Viñuela, F.; et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007, 68, 737–742. [Google Scholar] [CrossRef] [PubMed]
- Falcone, G.J.; Kirsch, E.; Acosta, J.N.; Ms, R.B.N.; Bs, A.L.; Marini, S.; Chung, J.; Selim, M.; Meschia, J.F.; Brown, D.L.; et al. Genetically elevated LDL associates with lower risk of intracerebral hemorrhage. Ann. Neurol. 2020, 88, 56–66. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gurevitz, C.; Auriel, E.; Elis, A.; Kornowski, R. The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern? J. Clin. Med. 2022, 11, 536. https://doi.org/10.3390/jcm11030536
Gurevitz C, Auriel E, Elis A, Kornowski R. The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern? Journal of Clinical Medicine. 2022; 11(3):536. https://doi.org/10.3390/jcm11030536
Chicago/Turabian StyleGurevitz, Chen, Eitan Auriel, Avishay Elis, and Ran Kornowski. 2022. "The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?" Journal of Clinical Medicine 11, no. 3: 536. https://doi.org/10.3390/jcm11030536